471905-41-6 顺式-4-[(4-氯苯基)磺酰基]-4-(2,5-二氟苯基)环己烷丙酸

海关编码:29163990

• 生物活性 MK-0752是一种适度有效的γ-secretase（γ-分泌酶）抑制剂，降低Aβ40产量，IC50为5 nM。Phase 1/2。
• 体外研究 MK-0752 is identified as a moderately potent γ-secretase inhibitor, which reduces Aβ40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y cells. In vitro, MK-0752 blocks Notch-intracellular domain (ICD) cleavage and its subsequent nuclear translocation.
• 体内研究 MK-0752 (240 mg/kg) reduces the generation of newly produced Aβ with 90% decrease of AUV in the brain of rhesus monkeys. In addition, MK-0752 treatment increases levels of Aβ 1-14, Aβ 1-15, and Aβ 1-16 , while decreases levels of Aβ 1-17. In guinea-pigs, oral administration of MK-0752 (10 mg/kg -30 mg/kg) results in the dose-dependent reduction of Aβ40 in plasma, brain and cerebrospinal fluid (CSF) with IC50 of 440 nM in brain.
• 特征 MK-0752 is a moderately potent γ-secretase inhibitor.
• 生物活性 MK-0752是一种适度有效的γ-secretase（γ-分泌酶）抑制剂，降低Aβ40产量，IC50为5 nM。Phase 1/2。
• 靶点 Target Value γ secretase(Aβ40) Aβ (in human SH-SY5Y cells) 5 nM
• 体外研究 MK-0752是一种适度有效的γ-分泌抑制剂，其剂量依赖性减少人SH-SY5Y 细胞中Aβ40，IC50为5 nM。在体外，MK-0752阻断凹槽胞内结构域(ICD)裂解，以及随后的核易位。
• 体内研究 在猕猴大脑中，MK-0752(240 mg/kg)使新产生的Aβ生成减少，AUV下降90%。此外，MK-0752治疗增加Aβ 1-14，Aβ 1-15，和Aβ 1-16水平，而减少Aβ 1-17水平。在豚鼠体内，MK-0752 (10 mg/kg -30 mg/kg)口服给药导致Aβ40在血浆，大脑和脑脊液(CSF)中剂量依赖性减少，在大脑中IC50为440 nM。

医药